Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Vekemans

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
Plos One|November 22, 2013
Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trialMatthew B Laurens, Mahamadou A Thera, Drissa Coulibaly, et al.
The New England Journal of Medicine|September 16, 2011
A field trial to assess a blood-stage malaria vaccineMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
The Lancet. HIV|August 20, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trialShabir A Madhi, Anthonet L Koen, Alane Izu, et al.
The Journal of Infectious Diseases|June 15, 2016
Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity StudyJason A Regules, Susan B Cicatelli, Jason W Bennett, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
The Lancet. Microbe|December 22, 2024
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant dataPuck T Pelzer, Logan Stuck, Leonardo Martinez, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
The Journal of Infectious Diseases|August 26, 2010
Evaluation of the safety and immunogenicity of the RTS,S/AS01E malaria candidate vaccine when integrated in the expanded program of immunizationSelidji T Agnandji, Kwaku Poku Asante, John Lyimo, et al.
Plos One|November 22, 2013
Extended safety, immunogenicity and efficacy of a blood-stage malaria vaccine in malian children: 24-month follow-up of a randomized, double-blinded phase 2 trialMatthew B Laurens, Mahamadou A Thera, Drissa Coulibaly, et al.
The New England Journal of Medicine|September 16, 2011
A field trial to assess a blood-stage malaria vaccineMahamadou A Thera, Ogobara K Doumbo, Drissa Coulibaly, et al.
The Lancet. Infectious Diseases|July 26, 2011
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trialKwaku Poku Asante, Salim Abdulla, Selidji Agnandji, et al.
The Lancet. HIV|August 20, 2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trialShabir A Madhi, Anthonet L Koen, Alane Izu, et al.
The Journal of Infectious Diseases|June 15, 2016
Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity StudyJason A Regules, Susan B Cicatelli, Jason W Bennett, et al.
The Journal of Infectious Diseases|February 25, 2016
Demonstration of the Blood-Stage Plasmodium falciparum Controlled Human Malaria Infection Model to Assess Efficacy of the P. falciparum Apical Membrane Antigen 1 Vaccine, FMP2.1/AS01Ruth O Payne, Kathryn H Milne, Sean C Elias, et al.
The Lancet. Microbe|December 22, 2024
Effectiveness of the primary Bacillus Calmette-Guérin vaccine against the risk of Mycobacterium tuberculosis infection and tuberculosis disease: a meta-analysis of individual participant dataPuck T Pelzer, Logan Stuck, Leonardo Martinez, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
Lancet (London, England)|April 2, 2021
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trialKatherine R W Emary, Tanya Golubchik, Parvinder K Aley, et al.
Pageof 12